JUL 08, 2020 10:00 AM PDT

From Design to Implementation of SARS-CoV-2 Diagnostic Testing

  • Head of Infectious Disease Research, Diagnostics at Abbott

      Gavin A. Cloherty, Ph.D., is head of Infectious Disease Research for Abbott's diagnostics business. He provides scientific leadership in the area of infectious disease diagnostics by conducting groundbreaking clinical studies on hepatitis and HIV and developing new tests. As one of the top experts in the field, his innovative research is changing the way infectious diseases are being diagnosed to help improve patient outcomes. Gavin has more than 20 years of experience with Abbott and leads a team of scientists in the study of the viral diversity of HIV and hepatitis. His expertise is sought after globally through his established partnerships with commercial organizations, ministries of health, government agencies and academic institutions, such as the Centers for Disease Control and Prevention (CDC) and National Institutes of Health's AIDS Clinical Trial Group (ACTG) and Hepatitis B Research Network (HBRN). He has worked with the Republic of Georgia to help eradicate hepatitis C in the country, and is looking to expand these efforts to other regions of the world severely impacted by this disease. As a senior research scientist, Gavin assisted in the development and design of the Abbott Molecular RealTime tests and m2000 system. Throughout his career Gavin has published numerous studies, abstracts and posters. In addition to his impressive list of publications he also has been invited to speak at conferences around the world. Gavin graduated from the National University of Ireland, Galway, where he received his Ph.D. in molecular biology and a Bachelor of Science in microbiology and zoology. Gavin is a member of numerous professional and scientific societies, including the International AIDS Society and the American Association for the Study of Liver Disease. He also is a contributor to multiple editorial boards, including the Journal of Clinical Microbiology and Journal of Clinical Virology.

    • Professor & Vice Chair, Laboratory Medicine, and Medical Director of Clinical Laboratories & Molecular Pathology, Medical University of South Carolina
        Dr. Frederick (Rick) S. Nolte is currently Professor and Vice Chair for Laboratory Medicine in the Department of Pathology and Laboratory Medicine, and Medical Director of Clinical Laboratories and Molecular Pathology at the Medical University of South Carolina. He is active in and held positions of responsibility in the American Society for Microbiology, Association for Molecular Pathology, Clinical and Laboratory Standards Institute, Infectious Diseases Society of America, American Society for Clinical Pathology, American Association for Clinical Chemistry, and College of American Pathologists. He has authored numerous book chapters, practice guidelines, and more than 100 peer-reviewed publications in the areas of clinical microbiology and molecular diagnostics.
      • Associate Professor, Pathology, Harvard Medical School and Director of the Clinical Microbiology Laboratory, Beth Israel Deaconess Medical
          Dr. Kirby is an NIH-funded Principal Investigator in the Experimental Pathology Division of Beth Israel Deaconess Medical Center; Director of the Clinical Microbiology Laboratory at BIDMC; Program Director of the Medical Microbiology Fellowships at BIDMC; and an Associate Professor of Pathology at Harvard Medical School. He is Board Certified in Clinical Pathology, and is a Diplomat of the American Board of Medical Microbiology. From 2009-2012, he was the President of the Northeast Branch of the American Society of Microbiology. He also serves on the Editorial Boards of the Journal of Clinical Microbiology and Applied and Environmental Microbiology, and on the Harvard Committee on Microbiological Safety (COMS).

          Dr. Kirby received his B.S. degree from Yale College with a major in Molecular Biochemistry and Biophysics (MB&B). He interrupted his medical school training at the University of Pennsylvania for a two year stint at the National Institutes of Health as part of the NIH/HHMI Research Scholars Program. There he performed bacterial genetics research in the laboratory of Dr. Susan Gottesman in the National Cancer Institute. It was during this time that his interest in anything bacterial was firmly imprinted. On completion of medical school, he moved to Boston for a Clinical Pathology Residency at the Massachusetts General Hospital, where he also served as Clinical Pathology Chief Resident. He then completed a postdoctoral fellowship in bacterial pathogenesis in the Molecular Microbiology Department at the Tufts University Sackler School of Medicine in the laboratory of Dr. Ralph Isberg. On completion of his fellowship, he joined the faculty of Beth Israel Deaconess Medical Center.


        DATE:  July 8, 2020

        TIME:  10:00 am PDT


        Since it was first detected in Wuhan, China, in 2019, the novel coronavirus SARS-CoV-2 and the disease it causes, COVID-19, have spread rapidly across the globe. Slowing the spread of the disease relies on social distancing measures as well as widespread and rapid diagnostic testing. This webinar will discuss design and development of the SARS CoV-2 diagnostic assay as well as review different strategies on the implementation of SARS-CoV-2 molecular testing under FDA Emergency Use Authorization only (EUA) in a US Integrated Hospital Delivery Network (IDN).


        Learning Objectives:

        •  Understand Important assay features to consider during design and development of SARS CoV-2 assay

        • Review challenges and successes during implementation and scale up of SARS-CoV-2 Testing

        • Evaluate different applications of SARS-CoV-2 PCR results to understand disease status and progression




        Webinars will be available for unlimited on-demand viewing after live event.



        Show Resources
        Show Resources
        • See more
        Connect with us